Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Roche, Genentech open Boston R&D center

19 September 2026 · By · Wire by Fusion42

Published

19 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at mobihealthnews.com →

◆ Verified

Fusion42 · 19 September 2026 · Fusion42 review

Roche and Genentech have opened a 95,000-square-foot R&D center in Boston focused on cardiovascular, renal and metabolic diseases, leveraging AI and data science to accelerate drug discovery and clinical development.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You now face rising pressure to integrate AI deeply into your drug discovery process as Roche's new Boston center shows major pharma betting on AI to speed development in metabolic and cardiovascular disease research.

◆ Coverage

1 source · 19 Sep 2026

◆ Related on Wire

◆ Topics

Biotechaidrug-discoverybiotechrd-centercardiovascularmetabolic-disease